ClinicalTrials.gg
CompletedNCT02189837FLOREYUpdated Oct 3, 2018Results posted

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

A Phase 3 interventional study of Evolocumab and Atorvastatin in Primary Hyperlipidemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 2 sites in Australia. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-03.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
27th of 36
89 · median 308
Started
2014
with 2 others
Phase 3
22 of 36
none open now
Registered
20th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 27th largest by enrollment, is one of 3 that started in 2014, is one of 22 in phase 3, and was the 20th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.

03

Conditions studied

  • Primary Hyperlipidemia and Mixed Dyslipidemia

Keywords

  • Raised cholesterol
  • Cholesterol
  • Elevated Cholesterol
  • Hyperlipidemias
  • Dyslipidemias
  • Lipid Metabolism Disorders
  • Metabolic Diseases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-C at screening ≥ 100 mg/dL and ≤ 190 mg/dL
  • Fasting triglycerides ≤ 150 mg/dL
  • (BMI) between 18.0 and 32.0 kg/m\^2
  • Framingham cardiac risk score 10% or less

Exclusion criteria

Exclusion Criteria:

  • Treatment with a lipid-regulating drug or over the counter supplement in the last 3 months prior to screening
  • History of coronary heart disease (CHD) or CHD equivalent
  • Uncontrolled hypertension
  • Diabetes mellitus
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
89 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.

    Drug: Placebo to Evolocumab · Drug: Placebo to Atorvastatin

  • Active comparator
    Atorvastatin

    Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.

    Drug: Atorvastatin · Drug: Placebo to Evolocumab

  • Experimental
    Evolocumab

    Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.

    Biological: Evolocumab · Drug: Placebo to Atorvastatin

  • Experimental
    Evolocumab and Atorvastatin

    Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.

    Biological: Evolocumab · Drug: Atorvastatin

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • Administered by mouth

    Also known as: LIPITOR®

  • DrugPlacebo to Evolocumab

    Administered by subcutaneous injection

  • DrugPlacebo to Atorvastatin

    Administered by mouth

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)

    The fractional catabolic rate (the percentage of apolipoprotein B-100 in LDL which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation, and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.

    Time frame: Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.

Secondary outcomes

  1. Percent Change From Baseline in LDL-C at Day 50

    LDL-C was measured using ultrcentrifugation.

    Time frame: Baseline and Day 50

  2. Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)

    The production rate of apolipoprotein B-100 in LDL was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate the production rate.

    Time frame: Baseline and Day 50

  3. Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)

    The fractional catabolic rate (the percentage of lipoprotein(a) (Lp\[a\]) which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.

    Time frame: Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.

  4. Percent Change From Baseline in Lipoprotein(a) Production Rate (PR)

    The production rate of lipoprotein(a) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.

    Time frame: Baseline and Day 50

07

Results

Posted Aug 31, 2016

Participant flow

This study was conducted at 2 centers in Australia. The first participant was enrolled on 08 July 2014, and the last participant enrolled on 15 December 2014.

Participant flow — Overall Study
MilestonePlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Started22232321
Received treatment21222220
Completed20222019
Not completed2132
Withdrew: Withdrawal by subject2131
Withdrew: Sponsor decision0001

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)

The fractional catabolic rate (the percentage of apolipoprotein B-100 in LDL which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation, and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.

Time frame:
Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)
percent changePlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)-5.07 ± 26.0674.13 ± 24.8483.70 ± 26.06310.48 ± 26.68
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.018 · Ls mean treatment difference: 88.76 · 95% CI 15.73 to 161.80Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Atorvastatin vs Evolocumab and Atorvastatin · ANCOVA · p = <0.001 · Ls mean treatment difference: 236.35 · 95% CI 164.02 to 308.69Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Placebo vs Atorvastatin vs Evolocumab vs Evolocumab and Atorvastatin · ANCOVA · p = 0.005 · Treatment effect: 147.59 · 95% CI 44.80 to 250.38Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
SecondaryPercent Change From Baseline in LDL-C at Day 50

LDL-C was measured using ultrcentrifugation.

Time frame:
Baseline and Day 50
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Day 50
percent changePlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Percent Change From Baseline in LDL-C at Day 50-0.65 ± 3.09-45.25 ± 2.86-57.79 ± 3.15-83.19 ± 3.24
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = <0.001 · Ls mean treatment difference: -57.14 · 95% CI -65.91 to -48.38Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Atorvastatin vs Evolocumab and Atorvastatin · ANCOVA · p = <0.001 · Ls mean treatment difference: -37.95 · 95% CI -46.55 to -29.34Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Placebo vs Atorvastatin vs Evolocumab vs Evolocumab and Atorvastatin · ANCOVA · p = 0.003 · Treatment effect: 19.20 · 95% CI 6.93 to 31.47Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
SecondaryPercent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)

The production rate of apolipoprotein B-100 in LDL was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. LDL particles were isolated from plasma by sequential ultracentrifugation and isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate the production rate.

Time frame:
Baseline and Day 50
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)
percent changePlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)-3.80 ± 7.40-3.27 ± 7.05-20.45 ± 7.40-35.93 ± 7.57
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.11 · Ls mean treatment difference: -16.65 · 95% CI -37.37 to 4.08Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Atorvastatin vs Evolocumab and Atorvastatin · ANCOVA · p = 0.002 · Ls mean treatment difference: -32.66 · 95% CI -53.19 to -12.13Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Placebo vs Atorvastatin vs Evolocumab vs Evolocumab and Atorvastatin · ANCOVA · p = 0.28 · Treatment effect: -16.01 · 95% CI -45.18 to 13.16Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
SecondaryPercent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)

The fractional catabolic rate (the percentage of lipoprotein(a) (Lp\[a\]) which is replaced, transferred or lost per unit of time) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.

Time frame:
Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)
percent changePlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)7.49 ± 9.1725.52 ± 8.925.37 ± 9.8164.57 ± 9.23
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.87 · Ls mean treatment difference: -2.12 · 95% CI -28.94 to 24.70Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Atorvastatin vs Evolocumab and Atorvastatin · ANCOVA · p = 0.003 · Ls mean treatment difference: 39.06 · 95% CI 13.52 to 64.59Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Placebo vs Atorvastatin vs Evolocumab vs Evolocumab and Atorvastatin · ANCOVA · p = 0.030 · Treatment effect: 41.18 · 95% CI 4.15 to 78.20Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
SecondaryPercent Change From Baseline in Lipoprotein(a) Production Rate (PR)

The production rate of lipoprotein(a) was measured at Baseline and Day 50 over 5 consecutive days using the stable isotope tracer, D3-leucine. Lp(a) was isolated from plasma using an immunoprecipitation method employing immunomagnetic beads and polyacrylamide gel electrophoresis. Isotopic enrichment was determined using gas chromatography-mass spectrometry. Mathematical modelling of the protein enrichment data was used to estimate protein catabolism.

Time frame:
Baseline and Day 50
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) Production Rate (PR)
percent changePlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Percent Change From Baseline in Lipoprotein(a) Production Rate (PR)3.52 ± 7.94-6.88 ± 7.72-35.91 ± 8.4916.40 ± 7.99
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.001 · Ls mean treatment difference: -39.43 · 95% CI -62.66 to -16.21Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Atorvastatin vs Evolocumab and Atorvastatin · ANCOVA · p = 0.039 · Ls mean treatment difference: 23.28 · 95% CI 1.16 to 45.40Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.
  • Placebo vs Atorvastatin vs Evolocumab vs Evolocumab and Atorvastatin · ANCOVA · p = <0.001 · Treatment effect: 62.72 · 95% CI 30.65 to 94.79Model includes terms for the 2 factors in the factorial design (placebo or evolocumab and oral placebo or statin), their interaction, and LDL-C level.

Adverse events

Collected over From first dose of study drug until day 73. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/21 (0%)5/21 (23.8%)
Atorvastatin—0/22 (0%)12/22 (54.5%)
Evolocumab—0/22 (0%)14/22 (63.6%)
Evolocumab and Atorvastatin—1/20 (5%)10/20 (50%)
Most frequent serious events
Most frequent serious events
EventPlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
Liver injuryHepatobiliary disorders0/210/220/221/20
Most frequent other events
Most frequent other events
EventPlaceboAtorvastatinEvolocumabEvolocumab and Atorvastatin
HeadacheNervous system disorders2/215/228/227/20
NauseaGastrointestinal disorders1/213/222/222/20
MyalgiaMusculoskeletal and connective tissue disorders1/211/220/222/20
Abdominal painGastrointestinal disorders0/212/220/221/20
Influenza like illnessGeneral disorders0/210/222/220/20
NasopharyngitisInfections and infestations1/211/222/220/20
PharyngitisInfections and infestations0/212/221/220/20
Upper respiratory tract infectionInfections and infestations0/212/220/221/20
Blood creatine phosphokinase increasedInvestigations0/212/220/221/20
Neck painMusculoskeletal and connective tissue disorders0/212/221/220/20

Baseline characteristics

The full analysis set includes all randomized participants who received any study drug.

Age, Continuous
Age, Continuous(years)PlaceboAtorvastatinEvolocumabEvolocumab and AtorvastatinTotal
Mean33.9 ± 12.730.4 ± 7.433.5 ± 11.631.0 ± 9.832.2 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtorvastatinEvolocumabEvolocumab and AtorvastatinTotal
Female00000
Male2122222085
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAtorvastatinEvolocumabEvolocumab and AtorvastatinTotal
American Indian or Alaska Native00000
Asian12137
Black or African American00033
Native Hawaiian or Other Pacific Islander00000
White1920201473
Other10102
Mixed Race00000
Screening LDL-C Level
Screening LDL-C Level(participants)PlaceboAtorvastatinEvolocumabEvolocumab and AtorvastatinTotal
< 130 mg/dL999835
≥ 130 mg/dL1213131250
LDL-C Concentration
LDL-C Concentration(mg/dL)PlaceboAtorvastatinEvolocumabEvolocumab and AtorvastatinTotal
Mean118.1 ± 18.1123.2 ± 21.3118.2 ± 18.4116.5 ± 23.7119.1 ± 20.2
08

Study locations

2 sites
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
09

References and documents

Publications

  • Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation. 2017 Jan 24;135(4):338-351. doi: 10.1161/CIRCULATIONAHA.116.025080. Epub 2016 Dec 9. PubMed 27941065 ↗
  • Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018 Jul 14;39(27):2577-2585. doi: 10.1093/eurheartj/ehy122. Erratum In: Eur Heart J. 2019 Jan 1;40(1):58. doi: 10.1093/eurheartj/ehy243. PubMed 29566128 ↗
  • Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1644-1655. doi: 10.1161/ATVBAHA.118.310882. Epub 2018 Jun 7. PubMed 29880491 ↗
  • Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. J Am Heart Assoc. 2019 Apr 2;8(7):e011781. doi: 10.1161/JAHA.118.011781. PubMed 30897995 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Feb 2015, 7 months.

Results were first posted in Aug 2016, 1 year 6 months after primary completion. A results delay was requested in Jan 2016.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2014
First posted
Jul 15, 2014
StartActual
Jul 8, 2014
Primary completionActual
Feb 13, 2015
CompletionActual
Mar 5, 2015
Results delay requested
Jan 5, 2016
Results first posted
Aug 31, 2016
Last update
Oct 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02189837
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 15, 2014
Start date
Jul 8, 2014
Primary completion
Feb 13, 2015
Completion
Mar 5, 2015
Results posted
Aug 31, 2016
Last update
Oct 3, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Evolocumab · Atorvastatin

Start the discussion